As an AURKB inhibitor, the small molecule inhibitor AZD1152 (commercial name barasertib) has demonstrated dose-dependent tumour-suppressive and apoptotic activity in multiple myeloma, lung, breast, colorectal and pancreatic cancer cell lines [49–51]. The gene discussed is AURKB; the disease is plasma cell myeloma.